Paper28828166
Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes.
Kumar J and 2 others. Int J Organ Transplant Med, 2017. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes. Papers, record 28828166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28828166
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17523697 | Calcineurin inhibitors in pediatric renal transplant recipients. | Paediatr Drugs | 2007 | https://conductscience.org/library/papers/17523697 | PubMed |
| 2 | 23415313 | Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results. | J Heart Lung Transplant | 2013 | https://conductscience.org/library/papers/23415313 | PubMed |
| 3 | 24266969 | Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. | Am J Transplant | 2013 | https://conductscience.org/library/papers/24266969 | PubMed |
| 4 | 24004351 | Growing experience with mTOR inhibitors in pediatric solid organ transplantation. | Pediatr Transplant | 2013 | https://conductscience.org/library/papers/24004351 | PubMed |
| 5 | 19295318 | Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. | Transplantation | 2009 | https://conductscience.org/library/papers/19295318 | PubMed |
| 6 | 20155724 | mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? | J Nephrol | 2010 | https://conductscience.org/library/papers/20155724 | PubMed |
| 7 | 23909498 | Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients. | Clin Transplant | 2013 | https://conductscience.org/library/papers/23909498 | PubMed |
| 8 | 21136903 | Urinary proteomic analysis of chronic allograft nephropathy. | Proteomics Clin Appl | 2008 | https://conductscience.org/library/papers/21136903 | PubMed |
| 9 | 15446315 | Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. | Transplantation | 2004 | https://conductscience.org/library/papers/15446315 | PubMed |
| 10 | 24175203 | Is it time to give up with calcineurin inhibitors in kidney transplantation? | World J Transplant | 2013 | https://conductscience.org/library/papers/24175203 | PubMed |
| 11 | 19384179 | Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. | Transplantation | 2009 | https://conductscience.org/library/papers/19384179 | PubMed |
| 12 | 24565231 | Conversion to mTOR-inhibitor-based immunosuppression: which patients and when? | Transplant Res | 2013 | https://conductscience.org/library/papers/24565231 | PubMed |
| 13 | 24309084 | Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization? | Int J Cardiol | 2014 | https://conductscience.org/library/papers/24309084 | PubMed |
| 14 | 24151517 | Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. | Clin Dev Immunol | 2013 | https://conductscience.org/library/papers/24151517 | PubMed |
| 15 | 19422337 | Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. | Am J Transplant | 2009 | https://conductscience.org/library/papers/19422337 | PubMed |
| 16 | 20463641 | Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. | Transplantation | 2010 | https://conductscience.org/library/papers/20463641 | PubMed |
| 17 | 21775930 | Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. | Transplantation | 2011 | https://conductscience.org/library/papers/21775930 | PubMed |
| 18 | 20061999 | Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. | Transplantation | 2010 | https://conductscience.org/library/papers/20061999 | PubMed |
| 19 | 21334736 | Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. | Lancet | 2011 | https://conductscience.org/library/papers/21334736 | PubMed |
| 20 | 21162600 | Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option? | Paediatr Drugs | 2011 | https://conductscience.org/library/papers/21162600 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 33816147 | Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review. | World J Transplant | 2021 | https://conductscience.org/library/papers/33816147 |
Source PubMed
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28828166
GET https://conductscience.org/api/papers/v1/28828166/references?page=2